Business Context and Reporting Period
This Form 8-K Current Report from Halozyme Therapeutics, Inc. covers the period from September 16, 2009, to September 30, 2009. The filing reports on unregistered sales of equity securities pursuant to Item 3.02.
Key Financial Metrics
- Proceeds from Warrant Exercise: Approximately $2.8 million in aggregate gross proceeds.
- Shares Issued: 1,263,429 shares of common stock issued upon exercise of "2004 Warrants."
- Potential Future Proceeds: Approximately $1.1 million remaining if all outstanding warrants are exercised.
- Remaining Shares Issuable: 492,857 shares remain issuable upon exercise of remaining 2004 Warrants.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the specific warrant transaction details.
Material Changes
The primary material change is the increase in outstanding common stock and cash proceeds resulting from the partial exercise of the 2004 Warrants during the reporting period. The transaction was conducted as a private placement exempt from registration requirements under Section 4(2) of the Securities Act.
Outlook, Risks, and Contingencies
Expiration Deadline: Any 2004 Warrants not exercised by 5:00 PM (Pacific) on October 12, 2009, will expire.
Contingency: The company may receive an additional $1.1 million in gross proceeds contingent upon the full exercise of the remaining 492,857 warrants before the expiration date.
Investor Verification Checklist
- Verify the exact number of shares issued (1,263,429) and the total gross proceeds ($2.8 million) in the company's updated capitalization table.
- Confirm the status of the remaining 492,857 warrants and whether they were exercised prior to the October 12, 2009, deadline.
- Review the impact of the new share issuance on existing shareholder dilution.
- Check subsequent filings to confirm if the potential $1.1 million in additional proceeds was realized.